ELISA Kits

OSM(Oncostatin M) is a protein that in humans is encoded by the OSM gene. OSM is a pleiotropic cytokine that belongs to the interleukin 6 group of cytokines. The OSM gene is mapped on 22q12.2. Of these cytokines it most closely resembles leukemia inhibitory factor(LIF) in both structure and function. Treatment with recombinant OSM leads to the inhibition of proliferation and changes in cellular morphology of a number of tumor cell lines derived from a wide variety of tissue types. OSM signals through cell surface receptors that contain the protein gp130. The type I receptor is composed of gp130 and LIFR, the type II receptor is composed of gp130 and OSMR.

OSM(Oncostatin M) is a protein that in humans is encoded by the OSM gene. OSM is a pleiotropic cytokine that belongs to the interleukin 6 group of cytokines. The OSM gene is mapped on 22q12.2. Of these cytokines it most closely resembles leukemia inhibitory factor(LIF) in both structure and function. Treatment with recombinant OSM leads to the inhibition of proliferation and changes in cellular morphology of a number of tumor cell lines derived from a wide variety of tissue types. OSM signals through cell surface receptors that contain the protein gp130. The type I receptor is composed of gp130 and LIFR, the type II receptor is composed of gp130 and OSMR.

Osteoprotegerin(OPG) is identical to osteoclastogenesis inhibitory factor(OCIF), a soluble member of the tumor-necrosis factor receptor family that inhibits osteoclastogenesis. OPG is considered to play an important role in the regulation of bone resorption by modifying osteoclast differentiation. Osteoprotegerin is an independent risk factor for the progression of atherosclerosis and onset of cardiovascular disease. It can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity. OPG system may play a critical role in the development of osteolytic bone disease in multiple myeloma and that targeting this system may have therapeutic potential. OPG also plays a role in the vascular system. The standard product used in this kit is recombinant OPG, a 55KDa glycoprotein.

Osteoprotegerin(OPG) is identical to osteoclastogenesis inhibitory factor(OCIF), a soluble member of the tumor-necrosis factor receptor family that inhibits osteoclastogenesis. OPG is considered to play an important role in the regulation of bone resorption by modifying osteoclast differentiation. Osteoprotegerin is an independent risk factor for the progression of atherosclerosis and onset of cardiovascular disease. It can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity. OPG system may play a critical role in the development of osteolytic bone disease in multiple myeloma and that targeting this system may have therapeutic potential. OPG also plays a role in the vascular system.

Osteopontin(OPN) also called urinary stone protein, secreted phosphoprotein 1(SPP1), bone sialoprotein, and early T lymphocyte activation 1(ETA1). Osteopontin is a phosphorylated glycoprotein secreted to the mineralizing extrOPNllular matrix by osteoblasts during bone development. It is believed to facilitate the attachment of osteoblasts and osteoclasts to the extrOPNllular matrix, allowing them to perform their respective functions during osteogenesis. Osteopontin is presumably involved in stone formation as stone matrix. The deduced protein sequence reveals a 317-amino acid protein(34,982 Da) containing a 16-amino acid hydrophobic signal sequence and a 33,352-Da protein destines to undergo extensive post-translational modifications before being secreted from the cell. The gene is located on human chromosome 4. The standard product used in this kit is recombinant human OPN, consisting of 17-314 amino acid sequence with the molecular mass of 32.9KDa. As a result of glycosylation, the

Osteopontin(OPN) also called urinary stone protein, secreted phosphoprotein 1(SPP1), bone sialoprotein, and early T lymphocyte activation 1(ETA1). Osteopontin is a phosphorylated glycoprotein secreted to the mineralizing extrOPNllular matrix by osteoblasts during bone development. It is believed to facilitate the attachment of osteoblasts and osteoclasts to the extrOPNllular matrix, allowing them to perform their respective functions during osteogenesis. Osteopontin is presumably involved in stone formation as stone matrix. The deduced protein sequence reveals a 317-amino acid protein(34,982 Da) containing a 16-amino acid hydrophobic signal sequence and a 33,352-Da protein destines to undergo extensive post-translational modifications before being secreted from the cell. The gene is located on human chromosome 4. The standard product used in this kit is recombinant mouse OPN, consisting of 284 amino acid sequence with the molecular mass of 31.5KDa. As a result of glycosylation, the mol

The platelet-derived growth factor(PDGF) is a mitogen derived from human platelets consisting of two related polypeptides termed A and B chains. The genes for PDGF A chain, B chain/c-sis, and the PDGF receptor are expressed in human malignant glioma cell lines. Normal human endothelial cells in culture express the B chain of PDGF, and that endothelial-derived PDGF B chain is synthesized as a predicted precursor polypeptide of Mr 27,281. The entire B chain of PDGF is highly(96%) homologous to a portion of p28sis, the transforming protein of simian sarcoma virus(SSV). It has been suggested that p28sis exerts its transforming potential by mimicking the growth promoting activity of PDGF and stimulating the cell in an autocrine manner. PDGF A-chain precursor polypeptide is assigned to the proximal long arm of chromosome 7, band q11.23. The human homolog(PDGF B-chain/c-sis) of the transforming gene of simian sarcoma virus is assigned to chromosome 22. The standard product used in this kit is

The platelet-derived growth factor(PDGF) is a mitogen derived from human platelets consisting of two related polypeptides termed A and B chains. The genes for PDGF A chain, B chain/c-sis, and the PDGF receptor are expressed in human malignant glioma cell lines. Normal human endothelial cells in culture express the B chain of PDGF, and that endothelial-derived PDGF B chain is synthesized as a predicted precursor polypeptide of Mr 27,281. The entire B chain of PDGF is highly(96%) homologous to a portion of p28sis, the transforming protein of simian sarcoma virus(SSV). It has been suggested that p28sis exerts its transforming potential by mimicking the growth promoting activity of PDGF and stimulating the cell in an autocrine manner. PDGF A-chain precursor polypeptide is assigned to the proximal long arm of chromosome 7, band q11.23. The human homolog(PDGF B-chain/c-sis) of the transforming gene of simian sarcoma virus is assigned to chromosome 22. The standard product used in this kit is

The platelet-derived growth factor(PDGF) is a mitogen derived from human platelets consisting of two related polypeptides termed A and B chains. The genes for PDGF A chain, B chain/c-sis, and the PDGF receptor are expressed in human malignant glioma cell lines. Normal human endothelial cells in culture express the B chain of PDGF, and that endothelial-derived PDGF B chain is synthesized as a predicted precursor polypeptide of Mr 27,281. The entire B chain of PDGF is highly(96%) homologous to a portion of p28sis, the transforming protein of simian sarcoma virus(SSV). It has been suggested that p28sis exerts its transforming potential by mimicking the growth promoting activity of PDGF and stimulating the cell in an autocrine manner. PDGF A-chain precursor polypeptide is assigned to the proximal long arm of chromosome 7, band q11.23. The human homolog(PDGF B-chain/c-sis) of the transforming gene of simian sarcoma virus is assigned to chromosome 22.